EurekAlert! In the Spotlight - Parkinson’s Disease

Welcome to In the Spotlight, where each month we shine a light on something exciting, timely, or simply fascinating from the world of science.

This month, we’re spotlighting Parkinson’s disease research in recognition of Parkinson’s Awareness Month. Here, we’ll share the latest research on Parkinson’s disease, how scientists are working to better understand its causes and progression, advances in treatment and care, and more.

Latest News Releases

Updates every hour. Last Updated: 21-Oct-2026 04:16 ET (21-Oct-2026 08:16 GMT/UTC)

4-May-2026

Inexpensive material compresses light, paving the way for photonic microcircuits in the terahertz range

Fundação de Amparo à Pesquisa do Estado de São Paulo
Peer-Reviewed Publication

Study shows that lead iodide can support phonon-polaritons, allowing radiation to be confined on a nanoscale and enabling new data transmission devices.

Journal: Nature Communications
Funder: Fundação de Amparo à Pesquisa do Estado de São Paulo

4-May-2026

Researchers uncover brain mechanism that may help slow Parkinson’s disease, curiously only in females

Texas A&M University
Peer-Reviewed Publication

By boosting nicotine‑responsive receptors — without using nicotine itself — scientists protected brain cells from degeneration.

Journal: JNeurosci
Funder: American Parkinson Disease Association

28-Apr-2026

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

Aligning Science Across Parkinson's
Grant and Award Announcement

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.

28-Apr-2026

Re-conceptualizing Parkinson’s disease as a lifelong neurobiological trajectory: A framework for prevention

Chinese Medical Journals Publishing House Co., Ltd.
Peer-Reviewed Publication

A review in Neuroprotection (2026) reconceptualizes Parkinson’s disease as a lifelong neurobiological process shaped by early-life vulnerability, cumulative environmental exposures, and resilience factors. The authors integrate developmental biology, epigenetics, neuroimmune mechanisms, and brain plasticity into a prevention-focused framework. They highlight how early risks and lifelong protective behaviors influence disease trajectory, while emphasizing the need for longitudinal studies, early biomarkers, and targeted interventions to enable prevention rather than late-stage treatment.

Journal: Neuroprotection

27-Apr-2026

Hydraulic brain: Body motion linked to fluid movement in the brain

Penn State
Peer-Reviewed Publication

The brain is more mechanically connected to the body than previously appreciated, Penn State scientists reported in Nature Neuroscience, noting the connection could be a potential biological mechanism underlying why exercise is thought to benefit brain health.

Journal: Nature Neuroscience
Funder: Pennsylvania Department of Health, American Heart Association

22-Apr-2026

Damage to brain’s white matter may play key role in neurodegenerative disease, and could be target for future treatments

Cambridge Stem Cell Institute
Peer-Reviewed Publication

In a new study published in Nature, Cambridge researchers have discovered that damage to white matter can trigger features associated with neurodegenerative disease. Unexpectedly, these are not harmful, but instead are essential components of brain regeneration.

Journal: Nature

21-Apr-2026

Why "brain fog" in Parkinson’s isn’t always what it seems

Boston University
Peer-Reviewed Publication

A new study led by experts at Boston University, published in the journal Neuropsychology, is the first to examine “global” metacognition, a term to describe how accurately people judge their everyday cognitive abilities, by directly comparing self-reported cognitive concerns with objective neuropsychological performance.

Journal: Neuropsychology

21-Apr-2026

Use of psychotropics increases already in the early stages of Parkinson’s disease

University of Eastern Finland
Peer-Reviewed Publication

Up to one in three people with Parkinson’s disease use at least one psychotropic medication, a recent study from the University of Eastern Finland shows. People with Parkinson’s disease were using psychotropics more frequently than controls already before the diagnosis, and psychotropic use increased as the disease progressed.

Journal: British Journal of Clinical Pharmacology